The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Also ‘life changing returns’!? Most current investors need this company to 3 or 4 bag just to break even. Maybe you mean new investors which in that case I don’t care about there life changing returns.
@Harchris…It is obvious that we are sat on different stages of our emotional investor ‘S’ curve. I am in the despondent/depression stage and you are at the denial stage.
Every investor is different for this very reason and most on here don’t understand that and think everyone is on a level par with each other. We are all on different paths. One persons large loss is another persons pocket change. Everyone is on a different time line. Some have time to wait, others are on their last legs. The traders will try and pool everyone into a group that fits their narrative; very much how politicians work. So they target the population where they will have most influence. For example, I have probably been GMs biggest critic. Everyone dismissed my comments at first (going back to November 2020) but now the general consensus is that GM was key to the downfall of this company and with it the nose dive of the share price.
Now, everyone agrees that GM was at fault, yet before he was the legacy, the knight in shining armour, everyone’s hero.
Btw not sure you can use EKF as an example of financial constraints….they just paid out another dividend.
@DRB, I understand the passage of text you have posted re hiberplex but I'm not sure it's of any relevance to Novacyt, this seems to be referring to treatment protocols, not diagnostics. I probably need a little more context tbh
I mean technically I'm on a loss but I'm not here to breakeven and get out again, I think ncyt have a fighting chance of developing into a leading diagnostics company and with it life changing returns.
@byp if some of that is directed at me well my average is a good bit below £3, I'm not deep underwater or desperate or any of those things - granted I've moved a serious amount of money in again at £2.50 to get the average this low...
I thought I was out for good earlier in the year and was happy with the profits I'd made, albeit much reduced on what they were at one point, but I simply believe the risk vs reward is asymmetrical now. I believe we are only so low because the previous administration (namely Graham) made some big mistakes / didn't care much for shareholder engagement and now we are being punished once again for not seeing an immediate change in communications from the new man in charge.
There are lots of unknowns and risks ahead but I still feel way more comfortable having all this money in a small cap with no financial constraints (EKF have £20m cash available for example), no risk of a placing and are perfectly placed to take advantage of the increased spending going into diagnostics post pandemic.
So no not all of us are in because we won't sell at a loss, many of us think this company at this price is as good value as it gets.
A little something I found on Hiberplex. Any scientists that can shed some light on the below extract?
*****
For patients at risk for the development of hypoxic-ischemic encephalopathy with MOF and coagulopathy, plasma exchange might be beneficial. Plasma exchange has been shown to reverse sepsis-induced MOF and effectively correct coagulopathy by removing cytokines and inflammatory mediators and restoring clotting homeostasis.247 Granted, further clinical studies are needed; however, combining CPB, mild hypothermia, and plasma exchange would provide maximum therapeutic support after cardiopulmonary arrest, and all of these therapies are clinically used in pediatric patients. This concept of “therapeutic hibernation and plasma exchange” (HIBERPLEX) was introduced for recalcitrant shock in the pediatric population.248 This approach could potentially provide neuroprotection, hemodynamic support, and reversal of MOF, thus targeting the major management challenges after prolonged cardiopulmonary arrest.
Qiagon have a Resplex test. Apparently it can detect upto 20 respiratory viruses. Not sure if this had been discussed. Thought it was interesting that it was the same name as ours. Could it be a similar test?
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.copanusa.com/wp-content/uploads/2019/04/321427213652_CVS-Chong_study.pdf&ved=2ahUKEwj3wYqWqOvzAhWuQ0EAHWeECcIQFnoECBsQAQ&usg=AOvVaw1bLTmiNQuWR5_dK0qXGBrP
https://trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003684947
https://trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003712352
https://trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003712360
A trademark application for Co-prep was submitted in August and published in September. Trademark applications for Resplex and Hiberplex were made last week.
Not sure novacyt often shoots about things...
They havent been shooting about co-prep, ImuPLEX, ResPLEX HiberPLEX etc. So does it mean theyre developping those for nothing ?
Not sure !
Thanks Larry, it states filed 20th Oct 2020 and published 15th September 2021. So published 6 weeks ago. Why haven't we heard anything about this. Kind of makes you feel that it isn't that great. Certainly sounds it but if ncyt arn't shouting about it I guess it's nothing. Good find though
Drb83 :
https://twitter.com/Larry64450205/status/1453431014450139139?t=W2AUkGJCP93MCpntln22HA&s=19
Source below.
It is primer design ltd, inventors are two staff members from ncyt.
Byp, you're focusing a lot on the technicals. What will be will be. If it goes lower, buy imo. If it goes higher. Great.
I'm a lth and what I'm really bothered about is the radio silence at the moment. That could break at anytime and without prior warning. When it does the the £2's will be no more. Omi
Larry, how sure are you that the write up is for the Primer Design application. They seem to have different GB no.s. can you clarify please.
@harchris…..You are right, I should not say absolute terms, what I mean is ‘if it gets to 200p’. It’s no different to when you made the same mistake of saying that the price wouldn’t drop to what it is today. Touché some might say!
Chart patterns I don’t care about such as fib charts and wave theories. Its all meaningless on AIM. What does matter is when we look from left to right and where the price is likely to bounce from. Any idiot can understand that pattern, even me! My point is that in the last 16 months we haven’t dropped at close to that level. Maybe they are testing the bottom but I have no faith in 250p holding now and I expect most are thinking the same. Some are desperately ramping hoping this is the bottom and we bounce and they make another 5 to 10 percent before it drops again. However, now there is more uncertainty and most will be wondering if that 16 month low close today means that they need to reset their low point. Either way, as I said, I’m on a massive loss and really do t care if it drops further. In my mind it will be a good thing for the reason explained earlier. If I had money to short, then it would be a good punt I think but risky but alas I never have done that. As soon as I do, I have no problems telling people I have gone short. Why would I! If it makes you all feel better, say I’m short, still doesn’t alter the fact that this share is one massive mistake that everyone made to invest. Everyone’s is on a loss. Those who pretend that they have a lower average are lying. No chance of you were in profit you would still be holding with everything that has happened to date and certainly since end of January. I’m guessing most are just long term traders though and have done well to date. Well today it changes. We hit a historic bottom. That’s the reality.
BYP
@byp well you don't care about charting and candlesticks and what have you so the actual close isn't that relevant, the shares traded lower than today's low on numerous occasions in October and every time they bounced back to 250p before the breakout. Whilst you are using certainties (*when it falls to low 200s) I'm happy to say it *might fall to low 200s, it *might once again bounce around here and then surge as anticipation of news builds or we *might wake up to a positive rns tomorrow and never see 250p ever again. I don't pretend to know anything for certain.
@harchris….yes the share price went below 250p a number of times. That’s not what I said though, I said this is the first time it has finished below 250p in 16 months. Let’s brush over that though. When it does fall to low 200p’s I doubt any will apologise to me though.
Also I don’t understand how people can be so thick with percentages. If my average is let’s say £8, that is currently 70% down. If the price drops to £2, my total loss is now 75%. So that 50p drop to £2 if it happens is only a 5% impact. That is nothing compared to the overall paper loss. Let me know if you want a picture drawn to help you understand some more. In fact if it goes to £2 perhaps we might get more institutions buying in as the price becomes more attractive to them and hopefully with less shares available, we have less day traders and ATs that can impact the daily fluctuations. So as I said, I really don’t care if it it drops to £2, hopefully it does and that will help me recover my loss more quickly.
https://www.nature.com/articles/s41467-020-19057-5
Another study it has been known for a while high viral load, high risk of severity. The average covid admission in the states costs $60,000....now if you can identify who to treat asap not only can you reduce cost of overall stay by length but you could stop admission all together with new drugs coming on the market and thus remove strain on NHS and risk of lockdowns etc....Huge potential saver and value in this test.
https://www.nature.com/articles/s41598-021-95197-y many more studies like this. It has been mentioned numerous times by synairgen holders and professors that if only there was a test to identify those...
@bluelight yeah the share price fell below 250p probably twenty times or more this month , each and every time popping back up and eventually breaking out to the upside. I imagine it'll do the same over the next week or so if no news.
250 isn't the support, its c246. 250 is just a psychological number, but it has traded below that pretty consistantly over the last week or two. It hasn't however dropped below the mid 240's so think you'll be pretty safe ;)
Larry most bizarre that a fabulous new innovation is not heralded more favourably by some posters who seem very vociferous in their criticism of the company. Perhaps they are digging furiously for some other excellent news.
Larry on the "Therapeutic methods of the invention" "The invention also provides a method of treating sars-cov-2 in a patient having a high viral load"
There are a lot of scientific studies around high viral load and role of inteferon (sng yes hence why i know) casanova labs have done a lot of studies. It is these people that get more ill so to say and require hospital intervention. A thinking and suggesting always has been from professors in covid that if you can identify the high viral load then you can identify those who need potential treatments aka interferon (sng) sooner and thus prevent hospitalisation and need for ventilators etc.
https://twitter.com/casanova_lab
And share price closed below 250p support, risking tomorrow going down more.
I have lost 50% of my investment - very disappointed
Not much réaction on social medias for this.
Im surprised because i find this very good. So, i try to bring attention with a New post.
Thanks to gggg for the original find of course.
https://twitter.com/Larry64450205/status/1453328036829466625?t=Y6w2b_OZZnbuH7Wlz8LQQQ&s=19
Advantages of the invention :
- New very sensitive method of SARS-CoV-2 detection
- No cross reactivity = No false positives
- Distinguish low viral loads from high viral loads ! = Determine level of infection
I like this part also :
"Therapeutic methods of the invention"
"The invention also provides a method of treating sars-cov-2 in a patient having a high viral load"